Glaxo Wellcome Zovirax holds onto 53% of acyclovir new Rxs in first full month of generics -- Scott-Levin.
Executive Summary
GLAXO ZOVIRAX HELD 53% SHARE OF NEW ACYCLOVIR Rxs IN MAY, the first full month in which generics of the herpes therapy were marketed, according to Scott-Levin data. Glaxo Wellcome's patent for acyclovir expired April 23; 17 ANDAs were approved that week ("The Pink Sheet" May 5, T&G-4). Generic acyclovir captured 2% of new acyclovir prescriptions in April.